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Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, SpainAbstractWe aimed to describe Pneumocystis jirovecii pneumonia (PCP) prevalence and features in children from sub-Saharan Africa and to investigate
PCP-associated risk factors. During 2006–2007 we used molecular methods to test children younger than 5 years old admitted with severe
pneumonia to a hospital in southern Mozambique for Pneumocystis infection. We recruited 834 children. PCP prevalence was 6.8% and HIV
prevalence was 25.7%. The in-hospital and delayed mortality were signiﬁcantly higher among children with PCP (20.8% vs. 10.2%, p 0.021, and
11.5% vs. 3.6%, p 0.044, respectively). Clinical features were mostly overlapping between the two groups. Independent risk factors for PCP
were age less than a year (odds ratio (OR) 6.34, 95% conﬁdence interval (CI) 1.86–21.65), HIV infection (OR 2.99, 95% CI 1.16–7.70),
grunting (OR 2.64, 95% CI 1.04–6.73) and digital clubbing (OR 10.75, 95% CI 1.21–95.56). PCP is a common and life-threatening cause
of severe pneumonia in Mozambican children. Mother-to-child HIV transmission prevention should be strengthened. Better diagnostic
tools are needed.
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E-mail: sandube@cica.esIntroductionPneumocystis jirovecii pneumonia (PCP) is a common opportu-
nistic infection in immunosuppressed patients, especially those
living with HIV. PCP usually affects aggressively the lungs,
rapidly causing respiratory failure with marked hypoxemia. In
developed countries, PCP remains one of the leading AIDS-Microbiol Infect 2015; 21: 1018.e9–1018.e15
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.07.011deﬁning diagnoses, both in the United States and Europe, ac-
counting for over 16% of all AIDS diagnoses in Europe in 2008
[1]. PCP incidence has declined since the introduction of highly
active antiretroviral therapy (HAART) [2]. Current cases of
PCP in adults are associated with undiagnosed HIV cases and
with nonadherence to HAART or PCP prophylaxis [3,4]. In
children from developed countries, PCP incidence has declined
from 25 cases per 1000 HIV-infected children in 1994 to fewer
than ﬁve cases per 1000 HIV-infected children in 2004 [5]. The
most important risk factor for PCP is a CD4 count lower than
200/mm3 in children older than 6 years and adults, or a
CD4 proportion lower than 15% in younger children [5–7].
Predictive factors at admission for PCP diagnosis in children
include HIV infection, age less than 6 months, high respiratoryious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Lanaspa et al. Pneumonia among Mozambican children 1018.e10rate, low oxygen saturation and absence of fever and
vomiting [6,7].
Data on paediatric PCP from developing countries are
scarce, especially from sub-Saharan Africa, and are mostly based
on small series of cases [8]. The prevalence of Pneumocystis
jirovecii in African children with severe pneumonia varies from
3.8% to 49% [9–15]. HIV infection and young age were asso-
ciated with PCP and PCP-associated mortality, which ranged
from 20% to 62.5%.
The present study aimed to determine the PCP prevalence
among children admitted with severe clinical pneumonia to a
district hospital in southern Mozambique and to describe clin-
ical, laboratory, microbiologic and radiologic features. Aetio-
logic investigation among admitted patients permitted a detailed
comparison between patients with and without PCP, and the
investigation of PCP-associated risk factors.MethodsStudy setting and population
This prospective study was conducted from September 2006
to September 2007 at Manhiça District Hospital, the referral
health facility for a rural area in southern Mozambique. The
Centro de Investigação em Saúde de Manhiça (CISM) has run
a Demographic Surveillance System since 1996, linked with a
morbidity surveillance system at Manhiça District Hospital
and peripheral health centers [16]. Such surveillance covered,
at the time of the study, an area of approximately 500 km2
and 80 000 persons. In 2005, the prevalence of HIV among
pregnant women attending the antenatal clinic was high
(23.6%), and the estimated prevalence among the birth cohort
was 3% [17]. At the time of the study, severe pneumonia
accounted for 16% of hospitalizations among children younger
than 2 years old and had an associated case-fatality rate of
11% [18].
Procedures for recruited children and sample
collection
This study was part of a larger project designed to investigate
the characteristics of children younger than 5 years old
admitted with respiratory distress. Children fulﬁlling the in-
clusion criteria and whose parents had signed an informed
consent form underwent study procedures. Children pre-
senting with clinical signs for more than 2 weeks and those
who were household contacts of know tuberculosis cases
were excluded. Anteroposterior chest radiographs were ob-
tained within the ﬁrst 48 hours of hospitalization. Pulse ox-
imetry (Nellcor, Boulder, CO) was used to determine oxygen
saturation, and nasopharyngeal aspirates (NPA) wereClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeccollected using NPAK kits (MPRO, Farmington Hills, MI).
Venous blood was obtained at admission for malaria diagnosis,
blood culture, full blood cell count and biochemical
determinations.
X-ray interpretation
Chest X-rays, performed with a Siemens machine, were
interpreted blindly by two independent readers following a
World Health Organization (WHO)-designed X-ray interpre-
tation protocol [19]. Episodes with consolidation and/or pleural
effusion were deﬁned as radiologically conﬁrmed pneumonia
(end point pneumonia). Other radiologic end points included
interstitial inﬁltrates or normal radiographs. A third reader
interpreted images with discordant results from the two pri-
mary readers.
Laboratory methods
Packed cell volume was measured with a haematocrit reader
(Hawksley and Sons, Lancing, UK). Thick and thin blood ﬁlms
for malaria diagnosis were processed and examined according
to standard methods [16]. Glycaemia was determined using
Accu-Chek (Roche, Mannheim, Germany), and blood lactate
levels were determined using Lactate Pro (FaCT Canada,
Quesnel, British Columbia, Canada) at the bedside. A haema-
tology analyser (Kx21; Sysmex, Denver, CO) and a biochem-
istry analyser (Vitros DT60; Ortho Clinical Diagnostics, Raritan,
NJ) were used. Blood cultures were processed and bacterial
isolates identiﬁed as previously described [20–22]. The pres-
ence of different respiratory viruses (inﬂuenza virus A and B,
respiratory syncytial virus A and B, parainﬂuenza virus 1, 2, 3
and 4, adenovirus, human rhinovirus, human metapneumovirus
and enterovirus) in NPA was determined using four different
PCRs [23].
HIV-speciﬁc procedures
Recruited study children were referred for HIV counselling and
testing, which required an additional parental consent. HIV-1
serodiagnosis was performed using a sequential testing algo-
rithm with two rapid HIV-1 antibody tests (Determine; Abbott
Laboratories, Abbott Park, IL; Unigold; Trinity Biotech, Bray,
Ireland). HIV infection was conﬁrmed in seropositive children
aged <18 months and older children with discordant cases using
HIV-1 DNA Amplicor Test 1.5 (Roche Molecular Systems,
Branchburg, NJ). HIV diagnosed children were followed up
according to national guidelines.
Molecular diagnosis of Pneumocystis jirovecii
Pneumocystis jirovecii infections were investigated in NPA sam-
ples using molecular methods. After digestion with proteinase
K at 56°C, DNA from P. jirovecii was extracted using thetious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1018.e9–1018.e15
FIG. 1. Study proﬁle.
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Three speciﬁc genes were targeted: (a) nested PCR of mtLSU
(mitochondrial large subunit) rRNA locus using pAZ 102-fE/rH
(external primer) and pAZ 102-fX/rY (internal primer); (b)
nested PCR of mtSSU (mitochondrial small subunit) rRNA lo-
cus using pAZ 112-10F/10R (external primer) and pAZ 112-13/
14 (internal primer); and (c) touchdown PCR of the DHPS
(dihydropteroate synthase) locus using primers DHPS-3 (GCG
CCT ACA CAT ATT ATG GCC ATT TTA AAT C) and DHPS-
4 (GGA ACT TTC AAC TTG GCA ACC AC) [24,25].
Deﬁnitions
Severe pneumonia was deﬁned as cough and/or breathing dif-
ﬁculties, plus increased respiratory rate according to age group
and chest indrawing. An increased respiratory rate was deﬁned
according to age following standard WHO deﬁnitions [26].
Fever was deﬁned as an axillary temperature of 37.5°C.
Nutritional status was based on weight-for-age z scores, which
were calculated using the least mean square method and the
2000 CDC Growth Reference (Centers for Disease Control
and Prevention, Atlanta, GA). PCP was deﬁned as having at least
two Pneumocystis jirovecii genes ampliﬁed by PCR in a child with
symptoms of pneumonia. This was decided to increase the
speciﬁcity of the deﬁnition. Coagulase-negative staphylococci,
Bacillus species, or Micrococcus species were considered con-
taminants if isolated in the blood culture.
Case-fatality rates represent in-hospital mortality and do not
include patients who were lost from follow-up or were trans-
ferred. Mortality occurring within 21 days after hospital
discharge (delayed mortality) was investigated with De-
mographic Surveillance System data for children residing in the
CISM study area. Worsening was deﬁned as presence of sei-
zures, deep coma, prostration, low oxygen saturation, dehy-
dration or hypoglycaemia during admission in children without
these signs and symptoms at arrival, and as a decrease in oxygen
saturation of more than ﬁve percentage points at any time of
admission compared to saturation at arrival.
The rainy season was deﬁned as November to April and the
dry season as May to October.
Case management and treatment
Severe pneumonia was managed according to national guide-
lines, consistent with the Integrated Management of Childhood
Illness (IMCI) WHO guidelines [26]. Children requiring
specialized care were transferred to Maputo Central Hospital.
By the time children were recruited, Haemophilus inﬂuenzae b
or pneumococcal vaccines were not available in Mozambique.
National guidelines recommend the use of trimethoprim–
sulphamethoxazole for PCP prophylaxis in patients with a
conﬁrmed HIV infection.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectData management and statistical analysis
All study questionnaires were double-entered in FoxPro 5.0
(Microsoft, Redmond, WA). Statistical analyses were per-
formed by Stata 13 (StataCorp, College Station, TX).
Categorical variables were compared by chi-square test or
Fisher’s exact test. Normal distribution was assessed visually.
Means of normally distributed variables were compared by
Student’s t test. For nonnormally distributed variables, medians
and interquartile ranges are presented, and the Wilcoxon rank
sum test was used to assess differences.
Univariate and multivariate logistic regression analyses were
performed to assess associations between explanatory variables
and having PCP. For the multivariate analysis, automated
backward stepwise estimations were calculated using data from
patients with available HIV tests result. All variables associated
with PCP infection at a signiﬁcance level of p <0.10 in the
univariate analysis were included in the model. Odds ratios
(OR) and 95% conﬁdence intervals (CI) are presented.
Ethical approval
The study was approved by the Mozambican National Bioethics
Committee, the Institutional Review Board of the Hospital
Clinic (Barcelona, Spain) and the World Health Organization
review board.ResultsGeneral overview
During the study period (20 September 2006 to 20 September
2007), 2943 children were admitted to Manhiça District Hos-
pital, of whom 926 (31.5%) had severe pneumonia according to
the IMCI deﬁnition (Fig. 1). The parents of 834 of these patientsious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1018.e9–1018.e15
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study criteria) provided consent that permitted their children
to be included in the analysis. Consent for HIV screening was
obtained for 517 (62.0%) of the recruited patients, and 133
(25.7%) were HIV positive. The median age was 10.5 months
(interquartile range 4.2–20.8), 446 (53.5%) were infants (<12
months old) and 332 (36.8%) were girls. Blood culture results
were available for 730 children (87.5%), and 108 of them
(14.8%) were positive. The most frequently isolated bacteria
were Streptococcus pneumoniae (46/108, 42.3% of the positive
blood cultures), Haemophilus inﬂuenzae b (25/108, 23.1%) and
enteric Gram-negative bacilli (11/108, 10.2%). Viral detection in
NPA was available for 806 children (96.6%), and 392 (48.6%)
were positive for respiratory viruses, with multiple infections
being common (76/392, 19.4% of positive NPA). Malaria para-
sitemia results were available for 825 children (98.9%); 106
(12.9%) were positive.
Characteristics of patients according to PCP diagnosis
A total of 77 children (9.2%) had at least one Pneumocystis jir-
ovecii gene detected by PCR (Table 1). Among them, 20 (26%)
were positive for only one gene, which was in all cases mtLSU
rRNA. A total of 57 children (6.8%) had two or more genes
identiﬁed by PCR, thus fulﬁlling our PCP deﬁnition. Prevalence
of PCP among recruited patients was 14.3% (19/133) in HIV-
positive children and 3.3% (13/384) in HIV-negative children
(p <0.001; OR for being HIV positive among children with PCP,
4.76, 95% CI 2.24–10.09).
Children with a PCP diagnosis were younger than non-PCP
children (median age 3.6 months vs. 11.5 months, p <0.001;
Table 2), more frequently had gastrointestinal symptoms
(diarrhoea and/or vomiting) before admission and had lower
oxygen saturation at admission. A total of 47 children were
suspected to have PCP on clinical grounds, 19 in the PCP group
and 28 in the non-PCP group, yielding a sensitivity of 33.3% and
a speciﬁcity of 96.4% when compared to our PCR-based case
deﬁnition.
Regarding laboratory results, abnormal C-reactive protein
was more frequently detected in non-PCP children (36.4% vs.TABLE 1. Pneumocystis jirovecii molecular diagnosis: genes
ampliﬁed by gene group (n [ 834 total samples)
Characteristic mtLSU rRNA mtSSU rRNA DHPS
Only one gene (n = 20) 20 0 0
Two genes (n = 31) 30 28 4
All three genes (n = 26) 26 26 26
Positive samples, n (%) 76 (9.1) 54 (7.3) 30 (3.6)
DHPS, dihydropteroate synthase; mtLSU rRNA, mitochondrial large subunit;
mtSSU rRNA, mitochondrial small subunit.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infec62.4%, p 0.017; Supplementary Table 1). There were no dif-
ferences between the two groups in the rest of parameters.
Regarding coinfections, HIV prevalence was very high in both
groups but was signiﬁcantly higher in PCP children (59.4% vs.
23.5%, p <0.001). Respiratory viruses were commonly identi-
ﬁed in both groups, with human rhinovirus being the most
commonly identiﬁed virus in both groups (Table 3). Distribu-
tion of respiratory viruses was similar in PCP and non-PCP
children. Bacteraemia was frequent in both groups (14.6% vs.
14.8%), with Streptococcus pneumoniae being the most
commonly isolated bacterium in both groups.
Evolution during admission and outcome
Children with PCP experienced a signiﬁcantly worse disease
evolution during admission than non-PCP children (Table 2).
The in-hospital case-fatality rate was high in both groups: 20.8%
in children with PCP and 10.2% in non-PCP children (p 0.021).
Among surviving children from the Demographic Surveillance
System area, mortality up to 21 days after discharge (delayed
mortality) was also signiﬁcantly higher in the PCP group (11.5%
vs. 3.6%, p 0.044).
HIV infection did not affect the effect of PCP on mortality
(Supplementary Table 2; test of interaction p 0.459). On the
other hand, PCP seemed to be associated with worsening dis-
ease during admission among HIV-positive children, but not
among HIV-negative children, although the interaction was not
statistically signiﬁcant (test of interaction p 0.213).
Risk factors independently associated with PCP
In the multivariate analysis (Table 4), the risk of having PCP was
independently associated with being an infant, having positive
HIV status, having radiologic inﬁltrates, grunting and digital
clubbing. Vomiting, severe malnutrition, unilateral signs at res-
piratory physical examination and low oxygen saturation at
admission were not independently associated with PCP.DiscussionIn our series, Pneumocystis jirovecii played an important role in
children with severe pneumonia, particularly among HIV-
infected children. Overall, HIV prevalence was 25.6% and
PCP prevalence 6.8%, which is lower than previously reported
in most of the studies conducted in similar settings (3.8–21%)
[9,10,12,13,15]. This is probably explained by differences in age,
inclusion criteria and HIV prevalence. In previous studies, HIV’s
prevalence rates paralleled PCP’s reported prevalence [12,13].
Speciﬁcity of diagnostic tools may also partly explain the dif-
ferences in PCP prevalence between studies. In the present
study, two nested PCR and one touchdown PCR were used,tious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1018.e9–1018.e15
TABLE 2. Univariate analysis of clinical characteristics, evolution and outcome of patients according to PCP diagnosis
Characteristic
PCP Non-PCP
paValue n Value No.
Female sex 29 (51) 57 303 (39) 777 0.077
Age (years) 3.6 (2.8–5.0) 57 11.5 (4.8–21.5) 777 <0.001b
Age group 57 777 <0.001
Infants 48 (84.2) 398 (51.2)
1–5 years 9 (15.8) 379 (48.8)
HIV-positive status 19 (59.4) 32 114 (23.5) 485 <0.001
Admission during rainy season 33 (57.9) 57 465 (59.9) 777 0.772
Clinical suspicion of PCP 19 (33.3) 57 28 (3.6) 777 <0.001
Clinical history and referred symptoms
Previous severe malaria 1 (1.8) 57 41 (5.3) 777 0.240
Previous pneumonia admission 3 (5.3) 57 78 (10.0) 777 0.240
Fever 52 (91.2) 57 701 (90.2) 777 0.804
Cough 54 (94.7) 57 705 (90.7) 777 0.308
Breathing difﬁculty 53 (93.0) 57 679 (87.4) 777 0.213
Diarrhoea 21 (36.8) 57 177 (22.8) 777 0.016
Vomiting 18 (31.6) 57 167 (21.5) 777 0.077
Seizures 1 (1.8) 57 53 (6.8) 777 0.134
Intake refusal 12 (21.1) 57 163 (21.0) 777 0.989
Clinical signs at admission 777
Temperature 37.4 (1.0) 57 37.8 (1.3) 777 0.038
Hyperpyrexia ( 39°C) 7 (12.3) 57 170 (21.9) 777 0.087
Oxygen saturation (%), mean (SD) 83.6 (16.3) 57 91.4 (8.4) 777 <0.001c
Low oxygen saturation (< 90%) 29 (50.9) 57 201 (26.2) 777 <0.001
Tachypnea (age speciﬁc) 53 (93.0) 57 686 (88.3) 777 0.282
Nasal ﬂaring 36 (63.2) 57 400 (51.5) 777 0.088
Deep breathing 8 (14.0) 57 77 (9.9) 777 0.320
Crackles 35 (61.4) 57 527 (67.8) 777 0.318
Wheezing 7 (12.3) 57 171 (22.0) 777 0.084
Hypophonesis 1 (1.8) 57 37 (4.8) 777 0.293
Unilateral chest signs 17 (29.8) 57 144 (18.5) 777 0.037
Rhinorrhoea 9 (15.8) 57 109 (14.0) 777 0.713
Grunting 17 (29.8) 57 127 (16.3) 777 0.009
Stridor 0 (0) 57 11 (1.4) 777 0.366
Thoracoabdominal breathing 14 (24.6) 57 75 (9.7) 777 <0.001
Heart gallop 2 (3.5) 57 27 (3.5) 777 0.989
Pallor 7 (12.3) 57 97 (12.5) 777 0.964
Deep coma 0 (0) 57 26 (3.4) 777 0.161
Prostration 12 (21.1) 57 169 (21.8) 777 0.902
Dehydration 8 (14.0) 57 156 (20.1) 777 0.268
Oral candidiasis 10 (17.5) 57 63 (8.1) 777 0.015
Splenomegaly 6 (10.5) 57 81 (10.4) 777 0.981
Digital clubbing 2 (3.5) 57 7 (0.9) 777 0.066
Nutritional status 0.158
WAZ more than −1 SD 16 (28.1) 57 256 (33.3) 768
WAZ −1 to −3 SD 20 (35.1) 57 318 (41.4) 768
WAZ less than −3 SD 21 (36.8) 57 194 (25.3) 768
Worsening during admission 26 (45.6) 57 158 (20.3) 777 <0.001
Oxygen saturation 16 (28.1) 73 (9.4) <0.001
Prostration 11 (19.3) 64 (8.2) 0.005
Deep coma 0 (0) 21 (2.7) 0.209
Hypoglycaemia 5 (8.8) 11 (1.4) <0.001
Duration of admission, days. Median (IQR) 6.6 (3.9–11) 57 4.0 (2.7–6.6) 777 <0.001b
In-hospital CFR 10 (20.8) 48 72 (10.2) 709 0.021
Delayed mortalityd 3 (11.5) 26 17 (3.6) 475 0.044
Data are presented as n (%) or median (IQR) unless otherwise indicated.
CFR, case-fatality rate; IQR, interquartile range; PCP, Pneumocystis jirovecii pneumonia; SD, standard deviation; WAZ, weight-for-age z score.
ap value from chi-square test unless otherwise indicated.
bp value from Wilcoxon rank sum test.
cp value from Student t test.
dMortality during 21 days after discharge; includes only children from the study area.
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than immunoﬂuorescence [14,27].
The PCP case-fatality rate in our study was 20.8%, similar to
the one reported in a large study conducted in South Africa but
much lower than others conducted in Uganda, Malawi and
South Africa, which ranged 40–63% [9–15]. In some studies
patients had a more severe condition or were younger
[10,12,13], but not in others [9,15]. The present study was not
designed to assess the current management of PCP that could
explain these differences. Our reported case-fatality rate
associated with PCP remains extremely high.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectIn our series, clinicians suspected PCP in a third of the cases
on the basis of clinical grounds and radiologic results, leaving
most PCP cases undiagnosed. Molecular techniques are not
routinely available for clinicians in developing countries. Better
point-of-care diagnostic methods would therefore be highly
desirable, and clinicians should suspect PCP in children who
experience a bad response to common antibiotics.
Concurrent isolation of respiratory viruses in NPA and of
bacteria in blood culture was common in our study and was
more frequent than has been previously reported. In a study in
South Africa assessing 231 episodes of severe pneumonia inious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1018.e9–1018.e15
TABLE 3. Univariate analysis of microbiology results
according to PCP diagnosis
Microbiology result
PCP Non-PCP
pan (%) n n (%) n
Malaria slide positive 4 (7.1) 56 102 (13.3) 769 0.186b
Positive blood culture 7 (14.6) 48 101 (14.8) 682 0.966b
Streptococcus pneumoniae 4 (8.3) 42 (6.2) 0.540
Haemophilus inﬂuenzae b 0 (0) 25 (3.7) 0.395
Enteric Gram-negative bacilli 1 (2.1) 10 (1.5) 0.533
Non-typhi Salmonella 0 (0) 6 (0.9) 1.0
Staphylococcus aureus 1 (2.1) 6 (0.9) 0.385
Other (noncontaminants) 1 (2.1) 11 (1.6) 0.593
Positive CSF 1 (20.0) 5 14 (10.3) 136 0.435
H. inﬂuenzae b 0 (0) 9 (6.6) 1.0
S. pneumoniae 1 (20.0) 3 (2.2) 0.147
Other (noncontaminants) 0 (0) 2 (1.5) 1.0
Respiratory virus detected in NPA 29 (50.9) 57 363 (48.5) 749 0.725b
Human rhinovirus 18 (31.6) 176 (23.5) 0.169b
Adenovirus 3 (5.3) 99 (13.2) 0.082b
Respiratory syncytial virus A 2 (3.5) 47 (6.3) 0.569
Human metapneumovirus 4 (7.0) 35 (4.7) 0.348
Parainﬂuenza virus 1–4 1 (1.8) 30 (4.0) 0.718
Inﬂuenza virus A 2 (3.5) 19 (2.5) 0.657
Inﬂuenza virus B 3 (5.3) 15 (2.0) 0.108
Enterovirus 2 (3.5) 16 (2.1) 0.368
Virus detection
Single 23 (79.3) 293 (80.7)
Double 6 (20.7) 66 (18.2)
Triple 0 (0) 4 (1.1) 0.811b
CSF, cerebrospinal ﬂuid; NPA, nasopharyngeal aspirate; PCP, Pneumocystis jirovecii
pneumonia.
ap value from Fisher exact test unless indicated otherwise.
bp value from chi-square test.
TABLE 4. Multivariate analysis of independent risk factors for
PCP
Characteristic Adjusted OR
95% CI
pLower Upper
Age <1 year 6.34 1.86 21.65 0.003
HIV positive 2.99 1.16 7.70 0.023
Grunting 2.64 1.04 6.73 0.042
Digital clubbing 10.75 1.21 95.56 0.033
Radiologic inﬁltrates 3.56 1.26 10.04 0.017
CI, conﬁdence interval; OR, odds ratio; PCP, Pneumocystis jirovecii pneumonia.
CMI Lanaspa et al. Pneumonia among Mozambican children 1018.e14HIV-infected children, virus coinfection was found in 11–12%
of patients and bacteraemia in 6–10%, compared to 49% and
15% in the present study, respectively [11]. The difference in
virus coinfection is probably the result of the diagnostic
methods, as multiplex nested PCR was used in our study
compared to less sensitive antibody assays used in other
studies.
Limitations
The main limitation of this study derives from the lack of a
reference standard for PCP diagnosis. According to our deﬁ-
nition, the detection of a unique Pneumocystis gene on NPA was
considered negative, which may have led to misclassifying some
true cases. Children with only one positive gene were more
similar to children with no positive gene in terms of HIVClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecprevalence (21% vs. 23%) and proportion of infants (45% vs.
51%) than to children with two to three positive genes (HIV
prevalence 59%; proportion of infants 84%). However, the high
in-hospital mortality in the subgroup of one positive gene (25%)
might be evidence of misclassiﬁcation of some true cases, which
would lead to underestimating differences between the groups
considered in the analysis. On the other hand, detection of PCP
genes on NPA could be evidence of colonization instead of
infection. More invasive samples such as bronchoalveolar lavage
or lung biopsy might be useful for differentiating colonization
from infection, but the risk of these procedures was considered
excessive in symptomatic children.
Another important limitation is that HIV test results were
unavailable in 38% of the study children; these data were
excluded from the multivariate analysis. We did not collect data
on HIV or PCP management, or on immunologic status based
on CD4 count or presence of cytomegalovirus in blood (a
marker of severe immunosuppression) among HIV-positive
children. These are likely to have an effect on PCP-associated
mortality and prevalence.
Finally, the effect of smoke exposure, a known risk factor for
acquiring community pneumonia [28], was not controlled for. A
recent study in the same area showed that 8.7% of the children
had at least one parent who smoked, and that less than 2% of
the households had their cooking space located inside the
house (unpublished data).
Conclusions
PCP was common in the study children admitted with severe
pneumonia and was associated with high mortality and clinical
worsening of disease during admission. Clinicians should sus-
pect PCP in HIV-positive infants, especially those who experi-
ence evolution of disease during admission. However, older
children and HIV-negative patients can also have PCP. Clinical
signs and laboratory results could not reliably diagnose PCP, but
the presence of grunting and digital clubbing should trigger the
possibility of its diagnosis. Innovative diagnostic tools need to be
urgently developed for those populations most at risk. The
performance of the mother-to-child HIV transmission preven-
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